Literature DB >> 25778616

Can age at sexual maturity act as a predictive biomarker for prodromal negative symptoms?

Seethalakshmi Ramanathan1, Jean Miewald2, Debra Montrose2, Matcheri S Keshavan3.   

Abstract

BACKGROUND: Puberty and reproductive hormones have been identified as having a potential role in schizophrenia. Earlier reports have suggested associations between later age at puberty and schizophrenia in males. Similarly, associations have been reported between testosterone levels and psychotic symptoms. In this report, we examined the association between age at puberty and prodromal symptoms of psychosis.
METHODS: 58 child or adolescent family members of individuals with schizophrenia were interviewed using the Scale of Prodromal Symptoms and the Tanner Maturational Scale. Age at Tanner pubertal stage was determined and regression analyses were used to explore associations between prodromal symptoms and age at puberty.
RESULTS: Among males, delayed age at puberty was associated with greater severity of prodromal symptoms; the association between negative prodromal symptoms and delayed age was significant (p=0.001). In females, the association was not statistically significant.
CONCLUSIONS: Our results suggest that delayed age at puberty may be associated with negative prodromal symptoms of schizophrenia in males. Our findings suggest that delayed age at puberty could potentially be a predictive biomarker for psychopathology in males at risk for schizophrenia.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Negative symptoms; Psychosis; Puberty; Tanner stage

Mesh:

Substances:

Year:  2015        PMID: 25778616      PMCID: PMC4411182          DOI: 10.1016/j.schres.2015.02.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  44 in total

1.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.

Authors:  A Jablensky; N Sartorius; G Ernberg; M Anker; A Korten; J E Cooper; R Day; A Bertelsen
Journal:  Psychol Med Monogr Suppl       Date:  1992

Review 2.  Brain maturational processes and delayed onset in schizophrenia.

Authors:  M S Keshavan; G E Hogarty
Journal:  Dev Psychopathol       Date:  1999

3.  Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms.

Authors:  S van Rijn; A Aleman; L de Sonneville; M Sprong; T Ziermans; P Schothorst; H van Engeland; H Swaab
Journal:  Psychol Med       Date:  2011-01-21       Impact factor: 7.723

4.  Gender, social competence, and symptomatology in schizophrenia: a longitudinal analysis.

Authors:  K T Mueser; A S Bellack; R L Morrison; J H Wade
Journal:  J Abnorm Psychol       Date:  1990-05

5.  Sex hormones in psychotic men.

Authors:  Thomas J Huber; Christian Tettenborn; Eckhard Leifke; Hinderk M Emrich
Journal:  Psychoneuroendocrinology       Date:  2005-01       Impact factor: 4.905

6.  Gender differences in the left inferior frontal gyrus in normal children.

Authors:  Rebecca E Blanton; Jennifer G Levitt; Jeffrey R Peterson; David Fadale; Mike L Sporty; Mimi Lee; Dennis To; Elizabeth C Mormino; Paul M Thompson; James T McCracken; Arthur W Toga
Journal:  Neuroimage       Date:  2004-06       Impact factor: 6.556

Review 7.  Significance and meaning of neurological signs in schizophrenia.

Authors:  D W Heinrichs; R W Buchanan
Journal:  Am J Psychiatry       Date:  1988-01       Impact factor: 18.112

8.  Testosterone in first-episode schizophrenia.

Authors:  Eva Cesková; Radovan Prikryl; Tomás Kaspárek
Journal:  Neuro Endocrinol Lett       Date:  2007-12       Impact factor: 0.765

9.  Neurological soft signs in schizophrenia: a meta-analysis.

Authors:  Raymond C K Chan; Ting Xu; R Walter Heinrichs; Yue Yu; Ya Wang
Journal:  Schizophr Bull       Date:  2009-04-17       Impact factor: 9.306

10.  SPEM impairment in drug-naive schizophrenic patients: evidence for a trait marker.

Authors:  D Campion; F Thibaut; P Denise; P Courtin; M Pottier; D Levillain
Journal:  Biol Psychiatry       Date:  1992-11-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.